# US 2025/0144224 A1 · Abl inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144224 A1
- Document ID: US20250144224A1
- Status: Published application
- Kind: A1
- Application number: 18/718,781
- Filed: 2022-12-13
- Published: 2025-05-08
- Earliest claimed: 2021-12-13
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Kevan M. Shokat; Kevin Lou; Jack W. Stevenson
- Web page: https://patentgrep.com/patent/US20250144224A1

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- C07D 471/04: Ortho-condensed systems
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- C07D 417/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein, inter alia, are ABL inhibitors and uses thereof.

## Claims

### Claim 1

A compound comprising a monovalent ABL ATP binding site inhibitor covalently bound to a monovalent ABL myristoyl binding site inhibitor.

### Claim 2 (depends on 1)

The compound of claim 1, having the formula:
A-L1-B; or a pharmaceutically salt thereof, wherein
A is said monovalent ABL ATP binding site inhibitor;
B is said monovalent ABL myristoyl binding site inhibitor; and
L1 is a divalent linker.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The compound of claim 2, wherein
L1 is -L101-L102-L103-L104-L105-;
L101 is connected directly to said monovalent ABL ATP binding site inhibitor;
L101 is a bond, —C(O)—, —C(O)O—, —OC(O)—, —O—, —S—, —NR101, —C(O)NR101—, —NR101C(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L102 is a bond, —C(O)—, —C(O)O—, —OC(O)—, —O—, —S—, —NR102—, —C(O)NR102—, —NR102C(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L103 is a bond, —C(O)—, —C(O)O—, —OC(O)—, —O—, —S—, —NR103—, —C(O)NR103—, —NR103C(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L104 is a bond, —C(O)—, —C(O)O—, —OC(O)—, —O—, —S—, —NR104—, —C(O)NR104—, —NR104C(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L105 is a bond, —C(O)—, —C(O)O—, —OC(O)—, —O—, —S—, —NR105—, —C(O)NR105—, —NR105C(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
R101, R102, R103, R104, and R105 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CHCl2, —CHBr2, —CHF2, —CHI2, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCBr3, —OCF3, —OCI3, —OCH2Cl, —OCH2Br, —OCH2F, —OCH2I, —OCHCl2, —OCHBr2, —OCHF2, —OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim at position 6

-8. (canceled)

### Claim 9 (depends on 5)

The compound of claim 5, wherein L1 is -L101-(OCH2CH2)n-L104-L105-;
L101 is substituted oxo-substituted C1-C6 alkylene;
L104 is —NHC(O)—;
L105 is unsubstituted piperidinylene; and
n is an integer from 3 to 50.

### Claim 10

(canceled)

### Claim 11 (depends on 2)

The compound of claim 2, wherein A is a monovalent form of dasatinib, a monovalent form of ponatinib, a monovalent form of imatinib, a monovalent form of nilotinib, a monovalent form of bosutinib, a monovalent form of bafetinib, a monovalent form of olverembatinib, a monovalent form of tozasertib, a monovalent form of PF-114, a monovalent form of rebastinib, a monovalent form of danusertib, or a monovalent form of HG-7-85-01.

### Claim 12 (depends on 2)

The compound of claim 2, wherein A is a monovalent form of

### Claim 13 (depends on 12)

The compound of claim 12, wherein A is

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The compound of claim 13, wherein L1 is
wherein n is an integer from 3 to 50.

### Claim at position 14

-24. (canceled)

### Claim 25 (depends on 12)

The compound of claim 12, wherein A is

### Claim 26

(canceled)

### Claim 27 (depends on 25)

The compound of claim 25, wherein L1 is
wherein m and p are independently an integer from 3 to 50.

### Claim at position 18

-31. (canceled)

### Claim 32 (depends on 12)

The compound of claim 12, wherein A is

### Claim at position 20

-50. (canceled)

### Claim 51 (depends on 2)

The compound of claim 2, wherein B is a monovalent form of asciminib or a monovalent form of GNF-2.

### Claim 52 (depends on 2)

The compound of claim 2, wherein B is a monovalent form of

### Claim 53 (depends on 2)

The compound of claim 2, wherein B is

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56 (depends on 1)

The compound of claim 1, having the formula:

### Claim at position 27

-68. (canceled)

### Claim 69 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 70 (depends on 1)

A method of treating cancer in a subject in need thereof, said method comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73 (depends on 1)

A method of treating a neurodegenerative disease in a subject in need thereof, said method comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 74

(canceled)

### Claim 75 (depends on 1)

A method of treating an ABL-associated disease in a subject in need thereof, said method comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 35

-80. (canceled)

### Claim 81 (depends on 1)

A method of reducing the level of activity of ABL in a cell, said method comprising contacting the cell with an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 37

-85. (canceled)
